Halozyme Therapeutics (HALO) Total Liabilities (2010 - 2026)

Halozyme Therapeutics (HALO) has 17 years of Total Liabilities data on file, last reported at $2.5 billion in Q1 2026.

• Total Liabilities for Q1 2026 came in at $2.5 billion, up 43.1% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.5 billion (up 43.1% YoY), and the FY2025 annual result was $2.5 billion, up 45.71% from the prior year.
• Total Liabilities declined to $2.5 billion in Q1 2026 per HALO's latest filing, from $2.5 billion in the prior quarter.
• Over five years, Total Liabilities peaked at $2.5 billion in Q4 2025 and troughed at $902.0 million in Q1 2022.
• A 5-year average of $1.7 billion and a median of $1.7 billion in 2022 frame the typical range for Total Liabilities.
• The sharpest annual moves came in 2022 and 2023: Total Liabilities surged 95.58% in 2022, then declined 7.02% in 2023.
• A 5-year view of Total Liabilities shows it stood at $1.7 billion in 2022, then retreated by 1.33% to $1.6 billion in 2023, then gained by 3.04% to $1.7 billion in 2024, then surged by 45.71% to $2.5 billion in 2025, then declined by 0.95% to $2.5 billion in 2026.
• Business Quant data shows HALO's Total Liabilities at $2.5 billion in Q1 2026, $2.5 billion in Q4 2025, and $1.7 billion in Q3 2025.